How the StarD5 cholesterol transporter affects fatty liver disease

An ER Stress Inducible START Domain Cholesterol Transport Protein, StarD5; and Unique Role in Fatty Liver Disease

NIH-funded research VA Veterans Administration Hospital · NIH-11213944

This project looks at whether a protein called StarD5 that moves cholesterol inside liver cells helps cause or prevent fatty liver disease.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionVA Veterans Administration Hospital NIH-funded
Lab location1 site (Richmond, United States)
Project IDNIH-11213944 on NIH RePORTER

What this research studies

From a patient perspective, researchers are studying a liver protein named StarD5 that becomes active when liver cells are stressed and helps move cholesterol around inside the cell. They use lab experiments with cells and animal models and examine liver tissue to see whether changes in StarD5 alter cholesterol levels, fat buildup, insulin resistance, or signals that lead to scarring. The team focuses on how poor cholesterol handling in the cell’s endoplasmic reticulum might push simple fat accumulation toward inflammation and fibrosis. Results could point to molecular steps that new treatments might target to keep fatty liver from getting worse.

Who could benefit from this research

Good fit: People with nonalcoholic fatty liver disease (NAFLD), especially those with early fat buildup or signs of insulin resistance, would be most relevant to this research.

Not a fit: People with alcohol-related liver disease, liver conditions unrelated to cholesterol handling, or those with advanced cirrhosis are unlikely to see direct benefit from this specific work.

Why it matters

Potential benefit: If successful, this work could point to new treatments that target cholesterol transport in liver cells to prevent fatty liver from progressing to inflammation and scarring.

How similar studies have performed: Prior laboratory studies have linked cholesterol metabolism and ER stress to worsening fatty liver, but directly targeting StarD5 is a newer and less-tested approach.

Where this research is happening

Richmond, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.